TLOG Stock Overview
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
TetraLogic Pharmaceuticals Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$0.0001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | 9,900.00% |
1 Year Change | n/a |
3 Year Change | -99.81% |
5 Year Change | -98.38% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
TLOG | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 1.5% | 1.2% |
1Y | n/a | 1.1% | 24.7% |
Return vs Industry: Insufficient data to determine how TLOG performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TLOG performed against the US Market.
Price Volatility
TLOG volatility | |
---|---|
TLOG Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLOG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TLOG's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | n/a | www.tetralogicpharma.com |
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.
TetraLogic Pharmaceuticals Corporation Fundamentals Summary
TLOG fundamental statistics | |
---|---|
Market cap | US$2.43k |
Earnings (TTM) | -US$40.72m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs TLOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TLOG income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$40.72m |
Earnings | -US$40.72m |
Last Reported Earnings
Sep 30, 2016
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did TLOG perform over the long term?
See historical performance and comparison